Why the study?
Does mirabegron improve cardiac remodelling in a murine model of HFpEF?
Population
Male and female C57BL/6J mice exposed to metabolic and hypertensive stress to induce a model of heart…
Comparison
Mirabegron 2 mg/kg/day for 28 days. vs No mirabegron treatment.
Design
Preclinical
Follow-up
28 days
Key result
Mirabegron attenuated cardiac hypertrophy, left atrial enlargement, and left ventricular dilation in male mice with HFpEF, whereas females exhibited a less pronounced response.
Authors
Loading...
Sex-specific β3-AR effects on murine remodeling are hypothesis-generating; should not yet change clinical practice or trial design.
Does mirabegron improve cardiac remodelling in a murine model of HFpEF?
Pharmacological activation of β3-AR with mirabegron attenuates cardiac remodelling in a sex-dependent manner in a murine HFpEF model, with greater protective effects observed in males.
Thibodeau et al. (2026) studied Heart failure with preserved ejection fraction (HFpEF). Mirabegron vs. No mirabegron treatment was evaluated on Cardiac remodelling (cardiac hypertrophy, left atrial enlargement, and left ventricular dilation). Mirabegron attenuated cardiac hypertrophy, left atrial enlargement, and left ventricular dilation in male mice with HFpEF, whereas females exhibited a less pronounced response.